Is It OK to Take Supplements After a Prostate Cancer Diagnosis? by Stuart Jordan
We were recently asked by a newly diagnosed member of our groupâwho is preparing to begin treatmentâabout a dietary supplement he has been taking. His question had two parts: Could this supplement help with prostate cancer? And just as important, is it safe to keep taking it now?
It’s a fair question, and a very common one. Many supplements are marketed as supportive of prostate health, metabolism, or weight management, and it’s easy to assume they might be helpful during cancer treatment.
In my day job as publisher of the Wellness Letter, we often see how supplement claims outpace the science behind them. That’s why we rely on evidence-based research as the final word when exploring questions like these.
When we look closely at the research, the picture is clearer than the marketing suggests. So far, no dietary supplement has been shown in solid human studies to prevent, treat, or slow the progression of prostate cancer once diagnosed. Some supplements that once sounded promising haven’t held up in careful trials. Others affect lab markers, such as PSA, without improving outcomes that truly matter. In fact, some supplementsâlike high-dose vitamin E or seleniumâhave actually shown potential harm in trials.
Safety is just as important. Supplements and over-the-counter products can interact with medications, affect lab results, or interfere with how treatments work. This matters whether a man is on active surveillance, receiving hormone therapy, undergoing radiation therapy, or after treatment. Even products that seem harmless can complicate care if the medical team isn’t aware of them.
That’s why it’s essential to tell your doctors about every supplement and over-the-counter product you’re taking, not just prescriptions.
Instead of relying on supplements, focusing on overall healthâthrough diet, physical activity, weight management, and addressing true deficienciesâoffers a safer, better-supported path, especially when coordinated closely with your medical team.
DISCLAIMER: AnCan does not endorse Superpower or any of its products. All patients should discuss with their healthcare provider before using any of their products or any of the tests or advice in the article.
In another of the seemingly endless organizations offering premium health services, Superpower, founded in 2023, provides a fairly straightforward overview of the myriad tests and biomarkers available to Prostate Cancer patients (A Clear Guide to PCa Biomarkers). Seasoned AnCaners may find little new in here, especially those that attend or review many of the recent seminars/webcasts, but newcomers or those needing a refresher may find it helpful for further research or equipping you to be your own best advocate. The article hits many of the main tests with which we are all familiar, as well as some of the urine biomarkers (PCA3, Select MDx, ExoDX), without specifically endorsing any of them. It does touch on MRIs, but only multi-parametric, not bi-parametric MRIs, nor does it get into the trans-rectal versus trans-perineal debate. Be forewarned, there is information with which not everyone will agree (shocking, I know), but it is still a useful, albeit somewhat rudimentary tool.
(Here is my take on this article Therapeutic Use of Cannabis and Cannabinoids A Review JAMA Network, 11/26/25. On a personal side, I use CBD to help me sleep, and with a little (5%) addition of THC, it is a great anxiety calmer – Sally Torgeson, AnCan Blood Cancer Moderator & Multiple Myeloma Coach)
Unapproved Cannabis
The FDA has NOT approved the cannabis plant (botanical marijuana) for any medical use or indication.
Because it is classified as a Schedule I controlled substance under federal law, the FDA has not found it to be safe or effective for the treatment of any disease or condition [1.1, 1.7].
It is currently illegal to market CBD by adding it to food or labeling it as a dietary supplement in interstate commerce [2.1, 2.5].
FDA-Approved Cannabinoid Drugs
The FDA has approved a small number of prescription drugs containing either a purified cannabis-derived compound or synthetic cannabinoids:
Epidiolex (Cannabidiol or CBD): The only FDA-approved drug that contains a purified substance derived directly from the cannabis plant. It is approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex in patients one year of age and older [1.8, 2.1].
Marinol and Syndros (Dronabinol): Contain synthetic Î9-tetrahydrocannabinol (THC). Approved for:
Nausea and vomiting associated with cancer chemotherapy in patients who have not responded to conventional antiemetic treatments [2.2, 2.3].
Anorexia associated with weight loss in patients with HIV/AIDS [2.3].
Cesamet (Nabilone): Contains a synthetic substance that is chemically similar to THC. Approved for chemotherapy-induced nausea and vomiting [1.1, 2.3].
Regulatory Context
The FDA maintains its authority to regulate products containing cannabis or cannabis-derived compounds, even those derived from hemp (cannabis with less than 0.3% THC), under the Federal Food, Drug, and Cosmetic (FD&C) Act [1.4].
The FDA supports the development of new drugs through proper clinical trials to ensure they meet standards for safety and effectiveness [1.1, 2.4].
FDA-Approved Cannabinoid Drugs and Their Conditions
* Nausea and vomiting caused by cancer chemotherapy (when other antiemetics have failed) * Anorexia (loss of appetite) associated with weight loss in patients with HIV/AIDS
Cesamet (Nabilone)
Synthetic cannabinoid (similar to THC)
* Nausea and vomiting caused by cancer chemotherapy (when other antiemetics have failed)
Key Takeaway
Epidiolex is the only drug approved that contains a substance derived directly from the Cannabis plant (CBD). It represents the strongest evidence for cannabinoid efficacy in reducing seizure frequency in certain rare forms of epilepsy [1.1, 1.2].
The synthetic THC compounds (Dronabinol and Nabilone) are used primarily as a last resort for severe nausea/vomiting related to chemotherapy and for appetite stimulation in AIDS patients [1.2, 2.8].
The FDA has not approved the use of the whole cannabis plant for any medical condition, stressing the importance of standardized, tested pharmaceuticals for patient safety and proven effectiveness [1.7].1
 Off-Label Use vs. Unapproved Use
1. Off-Label Use (Legal and Regulated)
This applies only to drugs that the FDA has already approved.
What it is: Using an FDA-approved drug (like Epidiolex, Marinol, or Cesamet) for a condition, dose, or patient population that is not specifically listed on the drug’s official label.  Â
Legality: It is legal for a licensed physician to prescribe an approved drug for an off-label use if they believe it is medically appropriate for their patient.
FDA Position: The FDA does not regulate the practice of medicine; however, the manufacturer cannot market or promote the drug for the off-label use. The safety and efficacy for the off-label use have not been verified by the FDA’s rigorous testing process.
Example: A doctor prescribing Marinol (Dronabinol), which is approved for nausea from chemotherapy, to a patient for chronic pain. The drug is approved, but the condition (chronic pain) is not on the label.
2. Unapproved Use (Non-FDA Approved Products)
This applies to the cannabis plant itself and most CBD/cannabinoid products on the market.
What it is: Using the whole cannabis plant (botanical marijuana) or non-FDA-approved cannabis-derived products (like most CBD oils, edibles, or topicals) for any medical purpose.
Legality:
Federal: The whole plant is a Schedule I controlled substance and is not federally approved for any medical use.  Â
State: Use may be legal under state medical or recreational cannabis laws, but this does not change its status as an unapproved drug under federal FDA law.
FDA Position: The FDA considers these products unapproved drugs and/or illegally marketed products (especially when CBD is added to food or marketed as a dietary supplement), as they have not been tested for safety, effectiveness, or quality assurance.  Â
Example: A patient using a CBD tincture (which is not Epidiolex) to treat anxiety, or using THC flower to help with multiple sclerosis symptoms.
To correspond with Sally, please send an email to info@ancan.org, and we’ll be sure to send along.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, Dec 15, 2025
AnCan thanks the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500Â https://www.fda.gov/media/76299/download
All AnCanâs groups are free and drop-in ⊠join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking FreelyâŠ1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation⊠1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely⊠4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editorâs Pick: Finishing 10x Pluvicto; and, following up post-surgery for BRCA germline Gent
Topics Discussed
Endorsing AnCan; 10 rounds of Pluvicto – with a break after 6; low dose estrigen enquiry; Newbie want to know when to intervene on recrrence post-surgery; Tempus report shows PTEN and more; cribriform favors radiation over surgery; time for another PSMA scan; IHT or mono daro – beware of gynecomastia; can reduciing daro dose loer fatigue?; more on cribriform and RT; debulking primary tumor post chemo; BRCA germline Gent wondes when to intervene with RT post RP – and if to include HT
Chat
Jeff Marchi – San Francisco
sent: 6:12 PM
friday this week
Thomas Matica
sent: 6:14 PM
Glad to hear Peter Kafka is doing well.
Stan Friedman
sent: 6:29 PM
after 5 sessions, my psa is now undetectable
Mark N
sent: 6:30 PM
What is the drug that was just discussed?
Larry Schuller – Alaska
sent: 6:31 PM
Mark, Pluvicto work the same way imaging for PSMA-PET scans do. Instead of just giving an image of where the cancer is, it delivers a higher dose that is therapeutic
Mark N
sent: 6:31 PM
Thanks!
AnCan–John A
sent: 6:33 PM
Lee–still undetectable psa?
Larry Schuller – Alaska
sent: 6:34 PM
Many side effecs of standard ADT is actually caused by estradiol deficiency (which is caused by the absence of testosterone). This deficiency is the same as what causes osteopoosis in post-menopausal women.
Larry Schuller – Alaska
sent: 6:35 PM
Men normally have between 15 and 50 levels of estradiol
Larry Schuller – Alaska
sent: 6:36 PM
Breast growth and nipple sensitivity is a side effect of standard ADT too, but at a lower incidence than with estradiol.
Jerry G, Brighton, MI
sent: 6:39 PM
I’ll add support for higher dose estradiol, for me in the absence of testosterone. My osteopenia cleared up, and I am now in the normal range for bone density. I have been on permanent ADT for almost 7 years now, and estradiol for just over 6. My PSA is still undetectable
Larry Schuller – Alaska
sent: 6:49 PM
Tom Miller’s Lymph nodes?
Lee Baylin, Baltimore
sent: 6:52 PM
Dr. John, I’m still undectable.
AnCan – rick
sent: 6:59 PM
Curtis DeVille an Channing Paller at Sibley
Bob Schwartz U.S.N. Venice, FL.
sent: 7:00 PM
Once again, many thanks to the Unknown Anonymous Benefactor, who is matching donations to AnCan. Please know that your kindness is very much appreciated. Good meeting as usual, unfortunately have to go early.
Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor showing promising early results in clinical trials for metastatic castration-resistant prostate cancer (mCRPC), often combined with AR inhibitors like darolutamide, targeting the PI3K pathway which is frequently altered in advanced prostate cancers, especially with PTEN loss, to control cell growth and survival, with studies aiming to find optimal doses and demonstrate improved survival and response rates.
Larry Schuller – Alaska
sent: 7:26 PM
Get a baseline bone density, too
Larry Schuller – Alaska
sent: 7:29 PM
Exercise program. A healthy body withstands the rigors of treatment better
RJ Smith (Seattle)
sent: 7:30 PM
Along with all the other tests, PROSTOX might help to know if you are prone to long-term side effects from the radiation. Most people aren’t. Like Rick said, though, if you’ve decided on radiation–might just take go for it. đ
Steve L
sent: 7:44 PM
By the way, My immunotherapy induced Pulmonary embolism cleared this summer after about 12 months. I started feeling better immediately. They have pulled me off Eliquis. I am back to scuba diving. Currently feeling very good.
AnCan–John A
sent: 7:46 PM
Noted, Steve. that’s good
Bruce Schrimpf
sent: 7:55 PM
Again A very good discussion! Should I not see you before, Merry Christmas!
Re: Second reads on PSMA-PET scan. I had a scan at Fred Hutch Cancer Center and the report was MUCH MORE detailed than the scan I had at my local imaging center. So, Second reads on the original scan imaging is valuable, in my opinion.
Larry Schuller – Alaska
sent: 8:17 PM
On top of that, the written report is only words. Actually showing the imaging to my surgeon saved me an extra surgery. Not mentioned on the report’s text wat that a reservoir from a prior surgery would complicate a robotic prostatectomy. It turns out that if a robotic had been started, it would have had to have been aborted, necessitating a subsequent open procedure.
Larry Schuller – Alaska
sent: 8:18 PM
Show your original imaging to your doctors, especially if approaching surgery
dan-s
sent: 8:21 PM
Thanks all for another great mtg – I have to leave (up early tomorrow)
AnCan – rick
sent: 8:22 PM
Gents – long posts in the Chat poses a problem when we write up these meetings. There is a limit in You Tube on what we can paste.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, Dec 9, 2025
AnCan thanks the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500Â https://www.fda.gov/media/76299/download
All AnCanâs groups are free and drop-in ⊠join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking FreelyâŠ1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation⊠1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely⊠4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editorâs Pick: Lotsa confusion throughout this week! To pick just one, Signatera MRD test.
Topics Discussed
Newbie has a great HCP team – but seeking more; Mayo bamboozles this Newbie – needs more and reliable information; another Newbie chose to leave himself on ADT for 5 years – and wonders about fatigue and weight gain he’s now shed w. GLP; muscle mass with low T; Regular finds Signatera MRD test – but it’s not yet FDA approved for prostate cancer… & Dr. Jack’s been following this test a long time; Epstein downgrades Gent from 4+5 to 4+3 – Kishan & MR Linac next; elevated liver enzymes after chemo; steady as he goes with 0.03 rise; what’s pituitary’s role for testosterone; PSA testing during Pluvicto
Chat
Alexander Lalov, Pendleton, IN
sent: 4:13 PM
Is the recording going to be made public?
Eric James; Tyler TX
sent: 4:13 PM
yes, on Youtube
AnCan – rick
sent: 4:14 PM
All our Recordings are posted on YuTube – over 700
Larry (Veteran, Alaskan)
sent: 4:16 PM
Check your camera shutter at the top of your screen
Dr. Ming Zhou Mount Sinai Health System Department of Pathology, Box 1194 Annenberg Bldg. 15th FL 1468 Madison Ave New York, NY 10029 Email: Ming.zhou@mountsinai.org Telephone: (212)241-8881
Jay – those are the 2 pathologists for a 2nd opinion.
Alexander Lalov, Pendleton, IN
sent: 5:27 PM
Bary, would you post the web address, please
Alexander Lalov, Pendleton, IN
sent: 5:28 PM
Oh, Withing is the name. Thnx!
John G.
sent: 5:28 PM
https://www.youtube.com/watch?v=Ado6dItMebE Yes, even on androgen deprivation therapy (ADT) with testosterone suppressed to near-zero (castration levels), you can increase muscle mass and strength through resistance training, though gains are typically modest and focused on counteracting atrophy rather than dramatic hypertrophy.[1][3] ## Evidence from Studies Multiple clinical trials show prostate cancer patients on ADT gaining muscle mass and fiber size after 12â20 weeks of supervised resistance training, including compound lifts like squats and presses, performed 2â3 times weekly. Progressive overloadâgradually increasing weightsâprevents fiber size decline in both type I and II muscles and boosts capillarization for better performance. These adaptations occur via mechanical loading and protein synthesis pathways independent of testosterone, such as IGF-1 signaling.
Larry (Veteran, Alaskan)
sent: 5:28 PM
YMCA “Livestrong” program is designed for cancer survivors. Look it up
Larry (Veteran, Alaskan)
sent: 5:29 PM
Government funded, so it is free and includes YMCA membership for the 12 week duration,
 Off-Label Use vs. Unapproved Use